Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study.

OBJECTIVE To assess the clinical feasibility of whole-body diffusion-weighted MRI (WB-DWI/MRI) for diagnosis and prediction of complete tumour resection in patients with suspected recurrent ovarian cancer. METHODS 51 females clinically suspected for ovarian cancer recurrence underwent 3-T WB-DWI/MRI in addition to contrast-enhanced CT. WB-DWI/MRI was assessed for detection of tumour recurrence, prediction of tumour extent and complete resection compared with CT. Tumour presence was confirmed by pathology obtained by surgery or biopsy, or by imaging follow-up. RESULTS WB-DWI/MRI showed 94% accuracy for detecting ovarian cancer recurrence, compared with 78% for CT (p = 0.008). WB-DWI/MRI showed better sensitivity [% (95% confidence interval)] than CT for detecting involvement of surgically critical tumour sites including mesenteric root infiltration [92 (62-100) vs 31 (10-61)], small bowel [93 (64-100) vs 21 (6-51)], colon carcinomatosis [91 (57-100) vs 27 (7-61)] and unresectable distant metastases [90 (54-99) vs 20 (4-56)]. WB-DWI/MRI correctly predicted complete resection in 33 of 35 (94%) patients eligible for salvage surgery compared with 17 of 35 (49%) for CT (p < 0.001). CONCLUSION WB-DWI/MRI allowed better detection of ovarian cancer recurrence and better prediction of complete resection than CT. Advances in knowledge: WB-DWI/MRI could assist in optimizing treatment planning for recurrent ovarian cancer, particularly by improving patient selection for salvage surgery, thus giving eligible patients the highest chance on prolonged survival and refraining patients who would not benefit from extensive surgery reducing related morbidity and mortality.

[1]  M. Forsting,et al.  Comparison of 18F–FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  L. Massuger,et al.  External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. , 2015, Gynecologic oncology.

[3]  K. Sugimura,et al.  Role of Diffusion Weighted Imaging and Contrast-Enhanced MRI in the Evaluation of Intrapelvic Recurrence of Gynecological Malignant Tumor , 2015, PloS one.

[4]  Michael Forsting,et al.  Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis: A Comparison to Whole-Body Magnetic Resonance Imaging Alone , 2014, Investigative radiology.

[5]  S. Dymarkowski,et al.  Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT , 2014, European Radiology.

[6]  L. Massuger,et al.  External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer , 2013, British Journal of Cancer.

[7]  M. Espada,et al.  Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma , 2013, European Radiology.

[8]  S. Derchain,et al.  Staging recurrent ovarian cancer with 18FDG PET/CT , 2012, Oncology letters.

[9]  D. Lorusso,et al.  The Role of Secondary Surgery in Recurrent Ovarian Cancer , 2012, International journal of surgical oncology.

[10]  G. Ferron,et al.  Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  R. Rouzier,et al.  Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. , 2011, Radiology.

[12]  G. Beets,et al.  Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer , 2011, European Radiology.

[13]  A. Reuss,et al.  Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO , 2010, International Journal of Gynecologic Cancer.

[14]  Stan B. Kaye,et al.  Imaging ovarian cancer and peritoneal metastases—current and emerging techniques , 2010, Nature Reviews Clinical Oncology.

[15]  H. Hricak,et al.  Prognostic Significance of Supradiaphragmatic Lymphadenopathy Identified on Preoperative Computed Tomography Scan in Patients Undergoing Primary Cytoreduction for Advanced Epithelial Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[16]  R. Low,et al.  Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. , 2009, AJR. American journal of roentgenology.

[17]  Gang Huang,et al.  CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. , 2009, European journal of radiology.

[18]  Nina Ditsch,et al.  PET-CT in recurrent ovarian cancer: impact on treatment planning. , 2008, Anticancer research.

[19]  R. Forstner Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI , 2007, European Radiology.

[20]  D. Collins,et al.  Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.

[21]  Sandra Nuyts,et al.  Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. , 2007, International journal of radiation oncology, biology, physics.

[22]  J. Huober,et al.  Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial , 2006, Annals of Surgical Oncology.

[23]  B. Duggan,et al.  Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. , 2005, Radiology.

[24]  E. Venkatraman,et al.  Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. , 2004, American journal of obstetrics and gynecology.

[25]  L. Balestreri,et al.  Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT. , 2002, La Radiologia medica.

[26]  H. Imhof,et al.  CT and MR Accuracy in the Detection of Tumor Recurrence in Patients Treated for Ovarian Cancer , 1993, Journal of computer assisted tomography.

[27]  I. Vergote,et al.  Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? , 2013, Gynecologic oncology.

[28]  C. Tropé,et al.  The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  S. Fujii,et al.  Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging , 2007, European Radiology.

[30]  G. V. von Schulthess,et al.  Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma , 2000, European Radiology.